Q32 Bio Inc.(QTTB) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update -- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open label extension (OLE) -- Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammat ...